000			02076 a2200577 4500
005			20250516141747.0
264		0	_c20140422
008			201404s 0 0 eng d
022			_a1930-739X
024	7		_a10.1002/oby.20356 _2doi
040			_aNLM _beng _cNLM
100	1		_aHughes, T E
245	0	0	_aAscending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. _h[electronic resource]
260			_bObesity (Silver Spring, Md.) _cSep 2013
300			_a1782-8 p. _bdigital
500			_aPublication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_a3-Hydroxybutyric Acid _xblood
650	0	4	_aAdiponectin _xblood
650	0	4	_aAminopeptidases _xantagonists & inhibitors
650	0	4	_aAnti-Obesity Agents _xadverse effects
650	0	4	_aAspergillus _xchemistry
650	0	4	_aBiological Products _xadverse effects
650	0	4	_aBlood Glucose _xmetabolism
650	0	4	_aBlood Pressure
650	0	4	_aC-Reactive Protein _xmetabolism
650	0	4	_aCholesterol, LDL _xblood
650	0	4	_aCyclohexanes _xadverse effects
650	0	4	_aDouble-Blind Method
650	0	4	_aFatty Acids, Unsaturated _xadverse effects
650	0	4	_aFemale
650	0	4	_aFibroblast Growth Factors _xblood
650	0	4	_aGlycoproteins _xantagonists & inhibitors
650	0	4	_aHumans
650	0	4	_aHunger _xdrug effects
650	0	4	_aInfusions, Intravenous
650	0	4	_aLeptin _xblood
650	0	4	_aLipids _xblood
650	0	4	_aMethionyl Aminopeptidases
650	0	4	_aMiddle Aged
650	0	4	_aObesity _xblood
650	0	4	_aSesquiterpenes _xadverse effects
650	0	4	_aTriglycerides _xblood
650	0	4	_aWeight Loss _xdrug effects
700	1		_aKim, D D
700	1		_aMarjason, J
700	1		_aProietto, J
700	1		_aWhitehead, J P
700	1		_aVath, J E
773	0		_tObesity (Silver Spring, Md.) _gvol. 21 _gno. 9 _gp. 1782-8
856	4	0	_uhttps://doi.org/10.1002/oby.20356 _zAvailable from publisher's website
999			_c22598945 _d22598945